OncoRx (US) signs up Response Biomedical's white cell monitor
This article was originally published in Clinica
Executive Summary
OncoRx (US) will distribute and sell Response Biomedical's (Canada) point-of-care granulocyte monitor once it has been approved in North America. Under the deal, OncoRx will sell the hand-held monitor and associated disposables for oncology outpatient use in Canada and the US. Response will receive a $750,000 milestone payment when the device is approved by the FDA.